FDA Feedback Supports 510(k) Path for Autonomix Sensing Platform, Clearance Targeted in 15 Months
AMIX sits 59% above its 52-week low of $2.44.
Summary
Autonomix completed an FDA pre-submission meeting and received feedback supporting a Class II 510(k) pathway for its standalone transvascular sensing platform, using substantial equivalence to an already-cleared device. The company targets potential U.S. clearance in approximately 15 months, subject to successful development and validation. This is a meaningful regulatory milestone for a micro-cap company with a market cap around $7.3 million and a cash runway only into Q1 2027. The news follows a series of dilutive financings and a recent reverse split, but the FDA feedback provides a clearer path to a first commercial product. Watch for updates on validation activities and the eventual 510(k) submission.
At the time of this announcement, AMIX was trading at $3.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $2.44 to $32.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.